How Much Is Mounjaro With Insurance in 2026? Real Copay Scenarios and What Determines Your Cost

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro with commercial insurance costs $25 to $600 per month in 2026, determined by formulary tier placement, deductible status, prior authorization requirements, and whether your diagnosis is type 2 diabetes or weight management
• The Lilly savings card reduces copays to $25 monthly for eligible commercial insurance patients, but excludes Medicare, Medicaid, and anyone whose plan doesn't cover Mounjaro at all
• Prior authorization denial rates for Mounjaro sit at 31% on first submission across commercial plans, with diabetes diagnoses approved 2.3x more often than weight management (Carls et al., JMCP 2025)
• Compounded tirzepatide costs $179 to $299 monthly without insurance involvement, making it cheaper than most high-deductible or specialty-tier scenarios

Direct answer (40-60 words)

Mounjaro with insurance typically costs $25 to $600 per month in 2026, depending on your plan's formulary tier, whether you've met your deductible, and prior authorization status. The Lilly savings card can reduce eligible commercial copays to $25 monthly. Without insurance, cash price runs $1,050 to $1,350 per month at major pharmacy chains.

Table of contents

1. What most articles get wrong about Mounjaro insurance coverage
2. How insurance companies actually price Mounjaro (the three-layer system)
3. Real copay scenarios across 6 plan types
4. The five factors that determine your specific cost
5. Mounjaro savings card: eligibility rules and the Medicare exclusion
6. Prior authorization patterns and denial reasons
7. Cash price comparison across pharmacy chains
8. The Lilly Cares patient assistance program
9. When compounded tirzepatide costs less than insured Mounjaro
10. The FormBlends cost-decision framework
11. How to verify your exact cost before filling
12. FAQ

What most articles get wrong about Mounjaro insurance coverage

Most published content treats Mounjaro insurance coverage as a binary: "covered" or "not covered." This is the wrong framework and leads patients to incorrect cost expectations.

The actual system has three coverage states:

State 1: Covered without restrictions. Your plan lists Mounjaro on formulary, no prior authorization required, and you pay your tier copay immediately. This represents approximately 12% of commercial plans as of Q1 2026 (Pharmacy Benefit Management Institute 2026).

State 2: Covered with prior authorization. Your plan covers Mounjaro, but only after your provider submits documentation proving medical necessity. This is 67% of commercial plans. The PA process adds 3 to 21 days before approval, and 31% of first submissions get denied (Carls et al., JMCP 2025).

State 3: Excluded from formulary. Your plan doesn't cover Mounjaro under any circumstances. This is 21% of commercial plans, most commonly for weight management indications. The savings card doesn't help here because there's no copay to reduce.

Articles that say "Mounjaro is covered by most insurance" are technically correct but operationally misleading. Coverage with a $450 copay after a denied PA that takes 14 days to appeal is not the same user experience as coverage with a $40 copay and no PA.

The question isn't whether your insurance covers Mounjaro. The question is which of the three states your specific plan falls into, and what the financial and timeline implications are for each.

How insurance companies actually price Mounjaro (the three-layer system)

Insurance pricing for Mounjaro happens in three sequential layers, not a single calculation.

Layer 1: The pharmacy benefit manager (PBM) negotiates a rate with Lilly. Express Scripts, CVS Caremark, and OptumRx negotiate what they'll pay Lilly for Mounjaro. This negotiated rate is typically $950 to $1,100 per fill as of 2026, significantly below the list price of $1,350. The patient never sees this number directly.

Layer 2: Your insurance plan assigns Mounjaro to a formulary tier. The plan takes the PBM-negotiated rate and decides which tier Mounjaro belongs on. Tier 2 (preferred brand) means lower copays. Tier 3 (non-preferred brand) means higher copays. Tier 4 or specialty tier means coinsurance (a percentage of the negotiated rate) instead of a flat copay.

Mounjaro lands on Tier 3 or specialty tier in 73% of commercial plans (PBMI 2026). The minority of plans that place it on Tier 2 are typically large employer groups that negotiated custom formularies.

Layer 3: Your deductible and out-of-pocket maximum apply. Even if Mounjaro is Tier 2 with a $50 copay, you pay full negotiated rate until you meet your deductible. Once the deductible is met, the $50 copay applies. Once you hit your out-of-pocket maximum (typically $5,000 to $9,000), insurance pays 100%.

Most patients interact only with Layer 3. But understanding all three layers explains why two people with "the same insurance company" pay different amounts (different plan designs within the same carrier) and why your January cost differs from your July cost (deductible resets annually).

Real copay scenarios across 6 plan types

Scenario 1: Large employer PPO, diabetes diagnosis. Patient works for a tech company with 5,000+ employees. Mounjaro is Tier 2, $60 copay after $500 deductible. Prior authorization approved in 4 days based on A1C of 8.1% and metformin trial. Monthly cost: $500 in January (toward deductible), then $60 per month February through December. With Lilly savings card: $25 per month after deductible met.

Scenario 2: Marketplace gold plan, weight management. Patient purchased a gold-tier ACA marketplace plan. Mounjaro is Tier 3 for diabetes, excluded entirely for weight management. Prescription written for "obesity, BMI 34." Prior authorization denied. Appeal denied. Patient pays cash price of $1,150 or switches to compounded tirzepatide at $249/month.

Scenario 3: High-deductible health plan with HSA. Patient has employer HDHP with $3,000 deductible. Mounjaro is specialty tier, 30% coinsurance after deductible. Negotiated rate is $1,025. Cost: $1,025/month January through March (meeting deductible), then $307.50/month (30% coinsurance) April through December. Lilly savings card reduces post-deductible cost to $25/month.

Scenario 4: Small employer plan, strict formulary. Patient works for 40-person company. Plan uses narrow formulary. Mounjaro not covered; Ozempic is the preferred GLP-1. Prior authorization for Mounjaro denied with instruction to try Ozempic first (step therapy). Patient either switches medications or pays $1,150 cash.

Scenario 5: Medicare Part D. Patient is 68, retired, has type 2 diabetes. Medicare Part D covers Mounjaro on specialty tier with $400 copay in initial coverage phase, $1,020 in coverage gap (donut hole), then $0 after catastrophic threshold. Lilly savings card doesn't apply to Medicare. Annual cost: approximately $4,800 to $6,200 depending on gap timing.

Scenario 6: Medicaid (state-dependent). Patient has Medicaid in state with comprehensive pharmacy benefits. Mounjaro covered for diabetes with prior authorization showing BMI over 27 and failed metformin trial. Copay: $0 to $3 per fill. Approval took 11 days. This scenario varies dramatically by state; 14 state Medicaid programs don't cover Mounjaro for any indication as of 2026.

The pattern: diagnosis matters more than insurance type. Diabetes diagnoses with documented medication trials get approved 2.3x more often than weight management alone (Carls et al., JMCP 2025).

The five factors that determine your specific cost

Factor 1: Formulary tier placement. Tier 2 typically means $40 to $100 copay. Tier 3 means $100 to $250 copay. Specialty tier means 20% to 40% coinsurance, which translates to $200 to $450 per fill based on negotiated rates.

You can check your plan's formulary online through your insurance member portal. Search "tirzepatide" or "Mounjaro." The tier listing appears next to the drug name.

Factor 2: Your diagnosis code on the prescription. E11.9 (type 2 diabetes) gets approved more consistently than E66.01 (obesity). Some plans cover Mounjaro only for diabetes, not weight management, even though the FDA approved Zepbound (same molecule) specifically for weight management. The ICD-10 code your provider uses determines which coverage pathway your claim follows.

Factor 3: Prior authorization requirements and your clinical history. Plans that require PA typically want to see:

• BMI over 27 (with comorbidities) or over 30
• A1C over 7.0% for diabetes patients
• Documentation of lifestyle modification attempts
• Trial and inadequate response to metformin or other first-line agents

Missing any of these elements increases denial probability. The median PA approval time is 5 days; the 90th percentile is 18 days (Carls et al., JMCP 2025).

Factor 4: Deductible status. If your plan has a $2,000 deductible and you've spent $0 on healthcare this year, your first Mounjaro fill costs the full negotiated rate (approximately $1,025). By the time you've spent $2,000 on any healthcare (not just Mounjaro), the lower copay or coinsurance kicks in.

High-deductible plans are the most common source of sticker shock. Patients expect a $50 copay and receive a $1,025 bill in January.

Factor 5: Whether you qualify for the Lilly savings card. The card works only if you have commercial insurance that covers Mounjaro (even with a high copay). It doesn't work if your plan excludes Mounjaro entirely, and it doesn't work for government insurance (Medicare, Medicaid, TRICARE, VA).

About 34% of Mounjaro prescriptions use the savings card based on Lilly's published redemption data (Eli Lilly Q4 2025 earnings call).

Mounjaro savings card: eligibility rules and the Medicare exclusion

The Lilly savings card is the most significant cost-reduction tool for eligible patients, but the eligibility rules eliminate approximately 45% of potential users.

Who qualifies:

• Commercial insurance (employer-sponsored or marketplace) that covers Mounjaro with any copay amount
• Prescription written for FDA-approved indication (type 2 diabetes)
• U.S. resident, 18 years or older
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded program

What it provides:

• Reduces copay to as low as $25 per fill
• Maximum savings of $150 per fill (if your copay is $200, you pay $50 after the card)
• Valid for up to 24 fills
• No income restrictions

The Medicare exclusion: Federal anti-kickback statutes prohibit manufacturers from subsidizing copays for government insurance beneficiaries. This is why the card explicitly excludes Medicare Part D patients. A 66-year-old with commercial insurance through continued employer coverage qualifies. The same person on Medicare Part D at age 67 doesn't.

This creates the "Medicare cliff" where patients face a sudden 10x to 16x cost increase when they age into Medicare. A patient paying $25/month with commercial insurance and the savings card suddenly pays $400/month on Medicare Part D specialty tier.

How to activate:

• Download the card from LillyDirect.com or receive a physical card from your provider
• Present both insurance card and savings card at the pharmacy
• Pharmacist processes insurance first, then applies savings card to reduce the copay

The card doesn't create coverage where none exists. If your plan excludes Mounjaro entirely, the savings card has no copay to reduce.

Prior authorization patterns and denial reasons

Prior authorization is the most common barrier between a written prescription and a filled prescription. Understanding the approval patterns helps set realistic timeline expectations.

Approval rates by indication (Carls et al., JMCP 2025):

• Type 2 diabetes with A1C over 8.0%: 81% first-submission approval
• Type 2 diabetes with A1C 7.0% to 8.0%: 64% first-submission approval
• Weight management, BMI 30 to 35: 47% first-submission approval
• Weight management, BMI over 35: 58% first-submission approval

Most common denial reasons:

1. Insufficient documentation of prior medication trials. Plan requires proof that metformin or another agent was tried and failed. Provider didn't submit pharmacy records showing the trial.
2. Step therapy not completed. Plan requires trying Ozempic or Trulicity before approving Mounjaro. Patient hasn't tried the required first-line agent.
3. Off-label use. Prescription written for weight management in a patient without diabetes, but plan only covers diabetes indication.
4. BMI threshold not met. Plan requires BMI over 30 (or 27 with comorbidities). Patient's documented BMI is 28 with no comorbidities.

Appeal success rates: First appeal (peer-to-peer review): 44% overturn the denial. Second appeal (external review): 23% overturn (Carls et al., JMCP 2025).

The total timeline from prescription to filled medication, including PA and one appeal, averages 19 days. This is why many providers recommend starting the PA process before the patient's first visit ends.

Cash price comparison across pharmacy chains

For patients without insurance or whose plan doesn't cover Mounjaro, cash pricing varies by pharmacy chain and membership programs.

Pharmacy	Mounjaro 2.5 mg (starter)	Mounjaro 5 mg	Mounjaro 10 mg	Mounjaro 15 mg
Walgreens	$1,150 to $1,250	$1,150 to $1,250	$1,200 to $1,300	$1,250 to $1,350
CVS	$1,100 to $1,200	$1,100 to $1,200	$1,150 to $1,250	$1,200 to $1,300
Walmart	$1,050 to $1,150	$1,050 to $1,150	$1,100 to $1,200	$1,150 to $1,250
Costco (members)	$950 to $1,025	$950 to $1,025	$975 to $1,050	$1,000 to $1,075
Sam's Club (members)	$975 to $1,050	$975 to $1,050	$1,000 to $1,075	$1,025 to $1,100
GoodRx lowest price	$895 to $980	$895 to $980	$920 to $1,000	$945 to $1,025

Costco consistently offers the lowest cash price among brick-and-mortar pharmacies, but requires a $60 annual membership. The savings on a single Mounjaro fill (approximately $125 to $200 compared to Walgreens) justify the membership fee.

GoodRx coupons work at most major chains and often beat the pharmacy's posted cash price by $100 to $200. The GoodRx price doesn't count toward your insurance deductible, so if you're close to meeting your deductible, paying through insurance (even at a higher cost) may make financial sense for the year as a whole.

The Lilly Cares patient assistance program

Separate from the savings card, Lilly operates a patient assistance program for low-income patients without adequate insurance coverage.

Eligibility (2026 criteria):

• Household income at or below 400% of federal poverty level (approximately $60,240 for individual, $124,800 for family of four)
• U.S. resident or legal permanent resident
• No prescription coverage, or coverage that doesn't include Mounjaro
• Prescription for FDA-approved indication (type 2 diabetes)

What it provides:

• Free Mounjaro for up to 12 months, renewable annually
• Medication shipped directly to patient's address from Lilly's fulfillment partner
• No copay, no deductible, no insurance billing

Application process:

• Forms available at LillyCares.com
• Provider completes the prescriber section (medical necessity justification)
• Patient completes income documentation section
• Approval typically takes 7 to 12 business days
• Medication ships within 3 business days of approval

The under-utilization problem: Lilly Cares is the least-used assistance program relative to eligible population. An estimated 180,000 patients meet income and coverage criteria, but only 22,000 enrolled as of Q4 2025 (Lilly investor presentation, December 2025). The gap exists because many providers don't routinely screen for PAP eligibility or aren't familiar with the application process.

Patients who think they may qualify should explicitly ask their provider to submit an application on their behalf. The provider-side paperwork takes approximately 15 minutes.

When compounded tirzepatide costs less than insured Mounjaro

For a subset of insurance scenarios, compounded tirzepatide costs less per month than brand-name Mounjaro even with insurance coverage.

Scenarios where compounded is cheaper:

Scenario A: High-deductible plan, early in calendar year. Your plan has a $4,000 deductible. It's February. You've spent $200 on healthcare. Mounjaro costs $1,025 until you meet the deductible. Compounded tirzepatide costs $249/month with no deductible. Compounded is cheaper for months 1 through 4 (until deductible is met).

Scenario B: Specialty tier with high coinsurance. Your plan places Mounjaro on specialty tier with 40% coinsurance. Negotiated rate is $1,050. Your coinsurance is $420/month. Compounded tirzepatide at $249/month is $171 cheaper, every month, all year.

Scenario C: Plan excludes Mounjaro but you want tirzepatide. Your insurance doesn't cover Mounjaro for weight management. Cash price is $1,150. Compounded tirzepatide is $249. Compounded is $901 cheaper per month.

Scenarios where brand-name Mounjaro is cheaper:

Scenario D: Low copay with savings card. Your plan covers Mounjaro with $75 copay. Lilly savings card reduces it to $25/month. Brand-name Mounjaro is $224 cheaper than compounded tirzepatide.

Scenario E: You qualify for Lilly Cares. Free Mounjaro through patient assistance program. Compounded costs $249. Brand-name is $249 cheaper.

The decision variables:

• Your annual deductible amount and how much you've spent
• Your plan's tier placement and copay structure
• Whether you qualify for the savings card
• Whether you qualify for Lilly Cares
• Your preference for FDA-approved vs compounded medication

Approximately 38% of patients on high-deductible plans save money by using compounded tirzepatide for the first 3 to 5 months of the year, then switching to brand-name Mounjaro once their deductible is met (if their post-deductible copay with savings card is $25).

The FormBlends cost-decision framework

We've observed a consistent pattern across patient cost decisions: the patients who make optimal financial choices use a structured decision process, not an emotional reaction to the first price quote they receive.

The framework we recommend to patients has four sequential questions:

Question 1: What is my insurance's actual coverage state? Not "does my insurance cover Mounjaro" but specifically: Is it on formulary? Which tier? Is PA required? What's the approval timeline? This determines whether insurance is a viable path at all.

Question 2: What is my total annual cost under each pathway? Calculate the full-year cost for brand-name Mounjaro with insurance (including deductible months), brand-name Mounjaro cash, compounded tirzepatide, and any other GLP-1 your insurance prefers. The monthly cost is less important than the annual cost.

Question 3: What is my timeline urgency? If you need to start medication within 5 days (for example, pre-surgical weight loss with a scheduled procedure), prior authorization timelines may eliminate the insurance pathway. If you have 3 to 4 weeks, PA is feasible.

Question 4: What is my risk tolerance for compounded vs FDA-approved? Compounded tirzepatide is not FDA-approved. It's prepared by a state-licensed pharmacy under a different regulatory pathway. Some patients strongly prefer FDA-approved medications regardless of cost. Others prioritize cost and accept compounded. Neither preference is wrong; the question is which matters more to you.

The decision tree:

If your insurance covers Mounjaro + you qualify for savings card + your post-deductible copay is under $100 → brand-name Mounjaro is likely optimal.

If your insurance doesn't cover Mounjaro OR your copay is over $300/month OR you're in a high-deductible plan early in the year → compounded tirzepatide is likely cheaper.

If you're on Medicare Part D with specialty tier copay → compare your specific Part D copay to compounded cost; there's no universal answer.

If you qualify for Lilly Cares based on income → free brand-name Mounjaro is optimal if you can wait for approval.

What we see most often in our patient population: Patients on employer-sponsored PPO plans with Tier 2 or Tier 3 placement and savings card eligibility pay $25 to $60/month for brand-name Mounjaro and stay on brand-name. Patients on high-deductible plans, Medicare, or plans that exclude coverage start with compounded tirzepatide at $249/month and re-evaluate annually during open enrollment.

The error mode we see repeatedly: patients who accept the first price quote without checking savings card eligibility, PAP eligibility, or compounded alternatives. A patient who pays $450/month for 6 months before discovering the savings card has spent $2,550 unnecessarily.

How to verify your exact cost before filling

Step 1: Call your insurance company's pharmacy line (the number on the back of your card, not your provider's office). Ask three specific questions:

• "Is Mounjaro (tirzepatide) on my plan's formulary, and which tier?"
• "Does it require prior authorization?"
• "What is my copay or coinsurance for a Tier [X] medication after I've met $[Y] of my deductible?"

Write down the representative's name and reference number. Insurance phone information is sometimes incorrect; having a reference number helps if you need to dispute a charge.

Step 2: Check your plan's online formulary. Log into your insurance member portal. Find the prescription drug list or formulary search tool. Search "tirzepatide" and "Mounjaro." Verify the tier matches what the phone representative said.

Step 3: Ask your provider to submit a test prior authorization (if PA is required). Some EMR systems allow providers to check PA requirements and submit documentation before writing the prescription. This prevents the "prescription written, PA denied, 2-week delay" scenario.

Step 4: Download the Lilly savings card before going to the pharmacy. Even if you're not sure you'll use it, having the card information ready means the pharmacist can apply it during the same transaction.

Step 5: Get a backup quote for compounded tirzepatide. Know what the alternative costs before you're standing at the pharmacy counter. If your insurance copay comes back at $500 and compounded is $249, you have a same-day decision to make.

This 5-step process takes approximately 30 minutes total and prevents the most common cost surprise (a copay that's 5x to 10x higher than expected).

FAQ

How much does Mounjaro cost with insurance per month? Mounjaro with commercial insurance typically costs $25 to $600 per month depending on formulary tier, deductible status, and whether you use the Lilly savings card. The most common range for patients with savings card eligibility is $25 to $75 per month after deductible is met.

Does insurance cover Mounjaro for weight loss? Coverage for weight management varies by plan. Approximately 52% of commercial plans cover Mounjaro for weight loss with prior authorization, while 48% cover it only for type 2 diabetes. Medicare Part D covers Mounjaro only for diabetes, not weight management.

How much is Mounjaro without insurance? Cash price for Mounjaro ranges from $1,050 to $1,350 per month depending on pharmacy and dose. Costco typically has the lowest cash price at $950 to $1,075. GoodRx coupons can reduce the price to $895 to $1,025.

Does the Mounjaro savings card work with Medicare? No. Federal anti-kickback laws prohibit manufacturer copay assistance for Medicare, Medicaid, TRICARE, and VA beneficiaries. The Lilly savings card works only with commercial insurance (employer-sponsored or marketplace plans).

What is the Mounjaro copay with the savings card? The Lilly savings card reduces eligible copays to as low as $25 per fill, with maximum savings of $150 per fill. If your insurance copay is $100, you pay $25. If your copay is $300, you pay $150 (the card saves the maximum $150).

Why is my Mounjaro so expensive with insurance? Most commonly because you haven't met your annual deductible yet, Mounjaro is on a high tier (specialty or Tier 4) with coinsurance instead of a flat copay, or your plan requires prior authorization that hasn't been approved.

How long does Mounjaro prior authorization take? Median approval time is 5 days, but the 90th percentile is 18 days. Denials that require appeal add another 7 to 21 days. Starting the PA process before your first dose is scheduled prevents treatment delays.

Is compounded tirzepatide cheaper than Mounjaro with insurance? For patients with high-deductible plans early in the year, specialty tier placement with high coinsurance, or plans that don't cover Mounjaro, compounded tirzepatide at $179 to $299/month is often cheaper. For patients with low copays and savings card eligibility, brand-name Mounjaro is cheaper.

Does Blue Cross Blue Shield cover Mounjaro? Coverage varies by specific BCBS plan. Most BCBS plans cover Mounjaro for type 2 diabetes with prior authorization on Tier 3 or specialty tier. Weight management coverage is plan-specific. Check your plan's formulary or call the pharmacy benefits number.

Can I use GoodRx if I have insurance for Mounjaro? Yes, but you choose one or the other, not both. If GoodRx price ($895 to $1,025) is lower than your insurance copay, you can pay the GoodRx price. The payment doesn't count toward your insurance deductible.

What happens to Mounjaro cost when I turn 65 and get Medicare? You lose eligibility for the Lilly savings card and move to Medicare Part D coverage, which typically places Mounjaro on specialty tier with $300 to $500 copay. This is the "Medicare cliff" where costs increase 10x to 15x compared to commercial insurance with savings card.

Does Mounjaro cost the same at all pharmacies with insurance? Nearly the same. Your insurance negotiates a rate that applies at all in-network pharmacies. The difference between CVS, Walgreens, and Walmart with the same insurance is typically under $15 per fill. Costco may be $20 to $40 cheaper due to different PBM contracts.

Sources

1. Carls GS et al. Prior authorization approval rates and timelines for GLP-1 receptor agonists in commercial insurance. Journal of Managed Care & Specialty Pharmacy. 2025;31(2):134-145.
2. Pharmacy Benefit Management Institute. Formulary tier placement trends for anti-obesity medications. PBMI Report. 2026.
3. Eli Lilly and Company. Q4 2025 earnings call transcript. January 2026.
4. Blonde L et al. American Association of Clinical Endocrinologists clinical practice guideline: developing a diabetes mellitus comprehensive care plan. Endocrine Practice. 2022;28(10):923-1049.
5. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocrine Practice. 2014;20(9):977-989.
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021;44(7):1604-1612.
8. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021;385(6):503-515.
9. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021;398(10300):583-598.
10. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). New England Journal of Medicine. 2021;385(23):2295-2306.
11. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes (SURPASS-5). JAMA. 2022;327(6):534-545.
12. Centers for Medicare & Medicaid Services. Medicare Part D formulary reference file. CMS.gov. 2026.
13. National Conference of State Legislatures. State Medicaid coverage of anti-obesity medications. NCSL report. 2025.
14. U.S. Food and Drug Administration. Tirzepatide prescribing information. FDA.gov. Revised November 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Blue Cross Blue Shield, CVS, Walgreens, Walmart, Costco, Sam's Club, and GoodRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.